Anna Lok

Anna Lok is a world-leading authority on hepatitis B virus infection and the prevention of HBV-associated hepatocellular carcinoma. Her landmark research established that long-term nucleoside/nucleotide analog therapy suppressing HBV replication significantly reduces HCC incidence in patients with chronic hepatitis B and cirrhosis. She has contributed to the development and evaluation of tenofovir, entecavir, and other antivirals for HBV and has defined optimal treatment paradigms for different patient populations. Her extensive epidemiological and clinical studies have informed national and international HBV treatment guidelines and HCC prevention programs globally.